Strong Sales and Earnings Send Exelixis Shares Higher
Exelixis, Inc. (NASDAQ: EXEL) continues to attract investor attention after reporting strong sales and earnings growth, while institutional buying has provided additional support for the stock. Shares have gained around 43.5% over the past year, according to recent market analysis.
The oncology-focused pharmaceutical company reported $628.7 million in second-quarter 2026 revenue, up from $568.3 million a year earlier. GAAP net income increased to $212.1 million, compared with $184.8 million in the same quarter of 2025.
Strong Cabozantinib Sales
A key contributor to Exelixis' performance remains its cabozantinib franchise. US net product revenue from the franchise reached approximately $573 million in the second quarter, representing about 10% year-over-year growth.
The company's continued ability to generate revenue from its established oncology portfolio has helped support earnings and cash generation.
Institutional Support
Institutional activity has also emerged as an important factor behind EXEL's recent performance. Recent analysis indicates that unusually large trading volumes have pointed to continued institutional interest, with several significant inflow signals recorded over the past year.
Institutional demand can provide additional liquidity and support for a stock, although it does not guarantee that the share price will continue rising.
Earnings Growth in Focus
Exelixis has maintained a strong earnings-growth profile. Recent analysis highlighted approximately 13% three-year sales growth and 83.6% three-year EPS growth, while earnings are expected to continue increasing.
At the same time, investors should pay attention to the company's updated outlook. Exelixis lowered its 2026 revenue guidance earlier in the year, reflecting uncertainty around the growth of some parts of its business.
EXEL Stock Outlook
The combination of strong earnings, growing sales and institutional interest has kept EXEL on the radar of momentum-focused investors.
However, after a substantial move higher, the stock may also become more sensitive to profit-taking, valuation concerns and changes in expectations for future earnings.
Traders and investors should monitor quarterly revenue growth, earnings guidance, institutional flows, cabozantinib sales and the company's pipeline developments for clues about the next major move.
Market Outlook
EXEL's fundamental picture remains supported by strong profitability and continued demand for its oncology products. The recent institutional interest adds another positive factor, but past performance is not a guarantee of future returns.
For now, the stock remains one to watch as investors assess whether strong fundamentals can support the next phase of its longer-term growth.
Disclaimer: This article is provided for informational and educational purposes only and does not constitute financial, investment, or trading advice. ForexNews.site does not provide personalized investment recommendations. Stock prices can rise or fall rapidly, and past performance does not guarantee future results. Always conduct your own research and carefully consider your financial circumstances and risk tolerance before making any investment decision.